BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 10990235)

  • 1. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials.
    Rostom A; Wells G; Tugwell P; Welch V; Dubé C; McGowan J
    J Rheumatol; 2000 Sep; 27(9):2203-14. PubMed ID: 10990235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of NSAID induced gastroduodenal ulcers].
    Hansen JM; Bytzer P
    Ugeskr Laeger; 2001 Oct; 163(44):6103-5. PubMed ID: 11715151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of NSAID-induced gastroduodenal ulcers.
    Rostom A; Wells G; Tugwell P; Welch V; Dube C; McGowan J
    Cochrane Database Syst Rev; 2000; (4):CD002296. PubMed ID: 11034748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of NSAID-induced gastroduodenal ulcers.
    Rostom A; Dube C; Wells G; Tugwell P; Welch V; Jolicoeur E; McGowan J
    Cochrane Database Syst Rev; 2002; (4):CD002296. PubMed ID: 12519573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of chronic NSAID induced upper gastrointestinal toxicity.
    Rostom A; Wells G; Tugwell P; Welch V; Dube C; McGowan J
    Cochrane Database Syst Rev; 2000; 2002(3):CD002296. PubMed ID: 10908548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.
    Koch M; Dezi A; Ferrario F; Capurso I
    Arch Intern Med; 1996 Nov; 156(20):2321-32. PubMed ID: 8911239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs: an update.
    Dajani EZ; Agrawal NM
    J Physiol Pharmacol; 1995 Mar; 46(1):3-16. PubMed ID: 7599335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs.
    Agrawal NM; Aziz K
    J Rheumatol Suppl; 1998 May; 51():17-20. PubMed ID: 9596550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
    Laine L
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study.
    Raskin JB; White RH; Jaszewski R; Korsten MA; Schubert TT; Fort JG
    Am J Gastroenterol; 1996 Feb; 91(2):223-7. PubMed ID: 8607484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.
    Jacobsen RB; Phillips BB
    Ann Pharmacother; 2004 Sep; 38(9):1469-81. PubMed ID: 15213313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
    Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
    Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of NSAID-gastropathy.
    Ardizzone S; Bianchi Porro G
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():33-6. PubMed ID: 9032581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol.
    Koch M
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S54-62. PubMed ID: 10379471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.